In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

YM BioSciences Inc.

Division of Gilead Sciences Inc.
www.ymbiosciences.com

Latest From YM BioSciences Inc.

Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs

Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.

Financing Business Strategies

Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib

With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.

Deals Commercial

What's Next On Gilead's Shopping List

With much of its cash held ex-US, Gilead is unlikely to undertake another large acquisition soon, even if there are logical reasons to bolster its NASH pipeline or try to acquire partner Galapagos. Firm is likely to follow Kite buyout with targeted cancer deals.

Business Strategies M & A

Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies

The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • York Medical Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Len Vernon, VP, Fin. & Admin.
    Ernest Wong, PhD, VP, Corp. Dev.
  • Contact Info
  • YM BioSciences Inc.
    Phone: (905) 629-9761
    5045 Orbitor Dr., Bldg. 11
    Ste. 400
    Mississauga, L4W 4Y4
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register